Keros Therapeutics Swings to $23.7M Loss as Takeda Takes Over Elritercept Development

Event summary

  • Keros reported a net loss of $23.7M in Q1 2026, down from $148.5M net income in Q1 2025 due to reduced R&D and licensing revenue.
  • R&D expenses fell 67% to $16.1M as Takeda assumed elritercept development costs.
  • Cash position declined slightly to $281.5M, with runway into first half of 2028.
  • Takeda plans Phase 3 trial for elritercept in myelofibrosis anemia.
  • General and administrative expenses decreased by $0.4M due to 2025 restructuring.

The big picture

Keros' strategic pivot reflects the biotech industry's reliance on big-pharma partnerships to fund late-stage development. The $281.5M cash position provides breathing room, but the company's valuation will increasingly hinge on Takeda's success with elritercept. This transition highlights the tension between maintaining independent pipeline momentum and leveraging external partnerships for commercialization.

What we're watching

Pipeline Progress
Whether Keros can advance rinvatercept in Duchenne muscular dystrophy and ALS while relying on Takeda for elritercept.
Financial Discipline
The pace at which Keros can maintain cost efficiency without compromising non-elritercept R&D.
Partnership Dynamics
How Takeda's Phase 3 trial expansion for elritercept will impact Keros' long-term revenue potential.